Fort LP’s Corcept Therapeutics CORT Stock Holding History

Fort LP’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,066	Closed	-$311K	–	279
2021 Q1	$311K	Buy	13,066 +1,574	+14%	+$42K	0.09%	232
2020 Q4	$301K	Buy	11,492 +705	+7%	+$14.9K	0.09%	236
2020 Q3	$188K	Buy	+10,787	New	+$172K	0.08%	292

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fort LP's CORT Position: Q2 2021 in Review

Fort LP sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 13,066 shares — an estimated $311K sold.

Fort LP first reported a position in CORT in Q3 2020 and held it in 3 quarters. The position peaked at $311K in Q1 2021. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

Fort LP reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
Fort LP sold 13,066 Corcept Therapeutics shares in Q2 2021, an estimated $311K.
Fort LP first reported a position in Corcept Therapeutics in Q3 2020 and held it in 3 quarters.
Fort LP's Corcept Therapeutics position peaked at $311K in Q1 2021.
199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Fort LP's 13F filing for Q2 2021, filed 13 Aug 2021.